Merck, SML1075-5MG, Atglistatin

Application
Atglistatin has been used as a selective inhibitor of adipose triglyceride lipase (ATGL).
Biochem/physiol Actions
Atglistatin is a selective inhibitor of adipose triglyceride lipase (ATGL).
Atglistatin is the first selective inhibitor of adipose triglyceride lipase (ATGL), the rate limiting enzyme involved in the mobilization of fatty acids from cellular triglyceride stores. Atglistatin has an IC₅₀ of 0.7 μM in E.coli and no activity against monoglycerol lipase (MGL), hormone-sensitive lipase (HSL), or pancreatic lipase and lipoprotein lipase PNPLA6 and PNPLA7. ATGL generates diacylglycerol from cellular triglyceride stores, which is then degraded by hormone-sensitive lipase (HSL) and monoglyceride lipase into glycerol and fatty acids, promoting the synthesis of lipotoxic metabolites that have been associated with the development of insulin resistance. Atglistatin inhibition of ATGL has been shown to reduce fatty acid mobilization in vitro and in vivo.
Other Notes
Produced under the license of University of Graz/Graz University of Technolog